Galetto-Lacour, Annick MD*; Alcoba, Gabriel MD, MPH*; Posfay-Barbe, Klara M. MD†; Cevey-Macherel, Manon MD‡; Gehri, Mario MD‡; Ochs, Martina M.§; Brookes, Roger H.¶; Siegrist, Claire-Anne MD†; Gervaix, Alain MD*
From the *Division of Pediatric Emergency Medicine; †Department of Child and Adolescent Medicine, Geneva University Hospitals and University of Geneva, Geneva; ‡Child and Adolescent Department, University Hospital, Lausanne, Switzerland; §Sanofi Pasteur, Marcy l’Etoile, France; and ¶Sanofi Pasteur, Toronto, Canada.
Accepted for publication May 13, 2013.
Sanofi Pasteur provided support for the serologic analyses. C.-A.S. declares a possible competing of interest, her institution received grants from Sanofi Pasteur to study mode of action of novel adjuvant, A.G. received research grants from Pfizer and GlaxoSmithKline and M.M.O. and R.H.B. are employees of Sanofi Pasteur. The authors have no other funding or conflicts of interest to disclose.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pidj.com).
Address for correspondence: Annick Galetto-Lacour, MD, Département de l’Enfant et de l’Adolescent, Hôpitaux Universitaires de Genève, Rue Willy-Donzé 6, 1211 Genève 14, Switzerland. E-mail: [email protected].
doi: 10.1097/INF.0b013e31829ba62a